Cargando…

Efficacy of stereotactic ablative radiotherapy (SABR) during anti-PD-1 in oligoprogressive non-small cell lung cancer and melanoma—a prospective multicenter observational study pointing out new unmet needs

Detalles Bibliográficos
Autores principales: Damen, Pim J. J., Verhoeff, Joost J. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080467/
https://www.ncbi.nlm.nih.gov/pubmed/37033340
http://dx.doi.org/10.21037/tcr-22-2841
_version_ 1785020929269563392
author Damen, Pim J. J.
Verhoeff, Joost J. C.
author_facet Damen, Pim J. J.
Verhoeff, Joost J. C.
author_sort Damen, Pim J. J.
collection PubMed
description
format Online
Article
Text
id pubmed-10080467
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-100804672023-04-08 Efficacy of stereotactic ablative radiotherapy (SABR) during anti-PD-1 in oligoprogressive non-small cell lung cancer and melanoma—a prospective multicenter observational study pointing out new unmet needs Damen, Pim J. J. Verhoeff, Joost J. C. Transl Cancer Res Editorial Commentary AME Publishing Company 2023-02-27 2023-03-31 /pmc/articles/PMC10080467/ /pubmed/37033340 http://dx.doi.org/10.21037/tcr-22-2841 Text en 2023 Translational Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Editorial Commentary
Damen, Pim J. J.
Verhoeff, Joost J. C.
Efficacy of stereotactic ablative radiotherapy (SABR) during anti-PD-1 in oligoprogressive non-small cell lung cancer and melanoma—a prospective multicenter observational study pointing out new unmet needs
title Efficacy of stereotactic ablative radiotherapy (SABR) during anti-PD-1 in oligoprogressive non-small cell lung cancer and melanoma—a prospective multicenter observational study pointing out new unmet needs
title_full Efficacy of stereotactic ablative radiotherapy (SABR) during anti-PD-1 in oligoprogressive non-small cell lung cancer and melanoma—a prospective multicenter observational study pointing out new unmet needs
title_fullStr Efficacy of stereotactic ablative radiotherapy (SABR) during anti-PD-1 in oligoprogressive non-small cell lung cancer and melanoma—a prospective multicenter observational study pointing out new unmet needs
title_full_unstemmed Efficacy of stereotactic ablative radiotherapy (SABR) during anti-PD-1 in oligoprogressive non-small cell lung cancer and melanoma—a prospective multicenter observational study pointing out new unmet needs
title_short Efficacy of stereotactic ablative radiotherapy (SABR) during anti-PD-1 in oligoprogressive non-small cell lung cancer and melanoma—a prospective multicenter observational study pointing out new unmet needs
title_sort efficacy of stereotactic ablative radiotherapy (sabr) during anti-pd-1 in oligoprogressive non-small cell lung cancer and melanoma—a prospective multicenter observational study pointing out new unmet needs
topic Editorial Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080467/
https://www.ncbi.nlm.nih.gov/pubmed/37033340
http://dx.doi.org/10.21037/tcr-22-2841
work_keys_str_mv AT damenpimjj efficacyofstereotacticablativeradiotherapysabrduringantipd1inoligoprogressivenonsmallcelllungcancerandmelanomaaprospectivemulticenterobservationalstudypointingoutnewunmetneeds
AT verhoeffjoostjc efficacyofstereotacticablativeradiotherapysabrduringantipd1inoligoprogressivenonsmallcelllungcancerandmelanomaaprospectivemulticenterobservationalstudypointingoutnewunmetneeds